Novartis lung drug wins EU nod, aiming for $500M sales

Novartis ($NVS) won European approval for its new COPD treatment Seebri Breezhaler, with potential peak sales of about $500 million. The Swiss drugmaker expects to launch by year's end. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.